Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With <i>FLT3</i>-ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
Mark J. Levis(Sidney Kimmel Cancer Center), Harry P. Erba(Michigan Center for Translational Pathology), Po‐Nan Wang(Chang Gung Memorial Hospital), Jörge E. Cortes(Augusta University Health), Mitsuhiro Yazawa(Daiichi Sankyo (United States)), Alexander E. Perl(University of Pennsylvania), Richard F. Schlenk(German Cancer Research Center), Mikkael A. Sekeres(University of Miami), Venkat Thodima(Daiichi Sankyo (United States)), Elżbieta Patkowska(Institute for Transfusion Medicine), Jaime E. Connolly Rohrbach(Daiichi Sankyo (United States)), Radovan Vrḫovac(University Hospital Centre Zagreb), Karima Imadalou(Daiichi Sankyo (United States)), Sergio Amadori(Polyclinic Medical Center), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Hee‐Je Kim(St. Mary's Hospital), Павел Зак(University Hospital Hradec Králové), Li Liu(Daiichi Sankyo (United States)), Akash Nahar(Daiichi Sankyo (United States)), Ken C. N. Chang(Daiichi Sankyo (United States)), Hervé Dombret(University of London Institute in Paris), Kristy Burns(Daiichi Sankyo (United States)), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 2
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k